Nanomedicine News

RSS
EC Approves Celgene’s ABRAXANE for First-Line Treatment of Non-Small Cell Lung Cancer

EC Approves Celgene’s ABRAXANE for First-Line Treatment of Non-Small Cell Lung Cancer

New Insight Report on Cancer Nanomedicine Market

New Insight Report on Cancer Nanomedicine Market

University of Manchester Scientists Selectively Target and Neutralize Cancer Stem Cells Using Graphene

University of Manchester Scientists Selectively Target and Neutralize Cancer Stem Cells Using Graphene

Innovative Approach Combines Nanotechnology and Molecular Biology to Tackle Brain Cancer

Innovative Approach Combines Nanotechnology and Molecular Biology to Tackle Brain Cancer

UCLA Researchers Devise Optimized Nanodrug Combination Approach

UCLA Researchers Devise Optimized Nanodrug Combination Approach

Rapid Diagnostic Test for Ebola and Other Fevers Using Multicolored Nanoparticles

Rapid Diagnostic Test for Ebola and Other Fevers Using Multicolored Nanoparticles

Tiny Molecule Holds Potential to Decrease Likelihood of Alcohol-Related Cancers in At-Risk Population

Tiny Molecule Holds Potential to Decrease Likelihood of Alcohol-Related Cancers in At-Risk Population

DNA Minicircles Show Promise for Early Detection of Cancer

DNA Minicircles Show Promise for Early Detection of Cancer

Researchers Devise Innovative Clot-Busting Technique Using Magnetic Nanoparticles

Researchers Devise Innovative Clot-Busting Technique Using Magnetic Nanoparticles

Celsion Presents Data on GEN-1 DNA-Based Immunotherapy for Advanced Platinum-Resistant and Recurrent Ovarian Cancer

Celsion Presents Data on GEN-1 DNA-Based Immunotherapy for Advanced Platinum-Resistant and Recurrent Ovarian Cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.